149 related articles for article (PubMed ID: 38548417)
1. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Schreibelt G; Duiveman-de Boer T; Pots JM; van Oorschot TGM; de Boer AJ; Scharenborg NM; van de Rakt MWMM; Bos K; de Goede AL; Petry K; Brüning M; Angerer C; Schöggl C; Dzionek A; de Vries IJM
Methods Cell Biol; 2024; 183():33-50. PubMed ID: 38548417
[TBL] [Abstract][Full Text] [Related]
2. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.
Cooles FAH; Anderson AE; Skelton A; Pratt AG; Kurowska-Stolarska MS; McInnes I; Hilkens CMU; Isaacs JD
Front Immunol; 2018; 9():755. PubMed ID: 29867920
[TBL] [Abstract][Full Text] [Related]
4. Automated Good Manufacturing Practice-compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines.
Uslu U; Erdmann M; Wiesinger M; Schuler G; Schuler-Thurner B
Cytotherapy; 2019 Nov; 21(11):1166-1178. PubMed ID: 31668486
[TBL] [Abstract][Full Text] [Related]
5. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Wyss T; Inoges S; de Vries IJM; Dartiguenave F; Jichlinski P; Derrè L; Coukos G; Melero I; Harari A; Romero P; Viganó S; Kandalaft LE
Eur J Cancer; 2020 Aug; 135():173-182. PubMed ID: 32590296
[TBL] [Abstract][Full Text] [Related]
6. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
[TBL] [Abstract][Full Text] [Related]
7. Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.
Sittig SP; de Vries IJM; Schreibelt G
Biomedicines; 2015 Dec; 3(4):282-303. PubMed ID: 28536413
[TBL] [Abstract][Full Text] [Related]
8. DC-Based Vaccines for Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33255895
[TBL] [Abstract][Full Text] [Related]
9. Human CD34
van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
[TBL] [Abstract][Full Text] [Related]
10. Acute aerobic exercise induces a preferential mobilisation of plasmacytoid dendritic cells into the peripheral blood in man.
Brown FF; Campbell JP; Wadley AJ; Fisher JP; Aldred S; Turner JE
Physiol Behav; 2018 Oct; 194():191-198. PubMed ID: 29763678
[TBL] [Abstract][Full Text] [Related]
11. The Superior Ability of Human BDCA3
Gu FF; Zhang K; Ma LL; Liu YY; Li C; Hu Y; Yang QF; Liang JY; Zeng YL; Wang Y; Liu L
Front Immunol; 2020; 11():1267. PubMed ID: 32655564
[TBL] [Abstract][Full Text] [Related]
12. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
Huber A; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2804. PubMed ID: 30559743
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
14. BDCA1
Sosa Cuevas E; Ouaguia L; Mouret S; Charles J; De Fraipont F; Manches O; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
Clin Transl Immunology; 2020; 9(11):e1190. PubMed ID: 33282290
[TBL] [Abstract][Full Text] [Related]
15. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
[TBL] [Abstract][Full Text] [Related]
16. Immunological responses to adjuvant vaccination with combined CD1c
Bloemendal M; Bol KF; Boudewijns S; Gorris MAJ; de Wilt JHW; Croockewit SAJ; van Rossum MM; de Goede AL; Petry K; Koornstra RHT; Figdor C; Gerritsen WR; Schreibelt G; de Vries IJM
Oncoimmunology; 2022; 11(1):2015113. PubMed ID: 36524210
[TBL] [Abstract][Full Text] [Related]
17. Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
Tel J; Koornstra R; de Haas N; van Deutekom V; Westdorp H; Boudewijns S; van Erp N; Di Blasio S; Gerritsen W; Figdor CG; de Vries IJ; Hato SV
J Transl Med; 2016 Apr; 14():88. PubMed ID: 27075584
[TBL] [Abstract][Full Text] [Related]
18. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.
Wimmers F; Schreibelt G; Sköld AE; Figdor CG; De Vries IJ
Front Immunol; 2014; 5():165. PubMed ID: 24782868
[TBL] [Abstract][Full Text] [Related]
19. Human CD141
Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
[TBL] [Abstract][Full Text] [Related]
20. Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.
van Beek JJ; Gorris MA; Sköld AE; Hatipoglu I; Van Acker HH; Smits EL; de Vries IJ; Bakdash G
Oncoimmunology; 2016; 5(10):e1227902. PubMed ID: 27853652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
